In Vivo takes an infographic look at where South Korea stands in the development of a wide-ranging set of drugs for Alzheimer’s disease and which companies are still in the challenging race.
With a few South Korean pharma firms now entering late-stage clinical trials for their Alzheimer's disease drug candidates, and many others actively pursuing development, hopes are brewing that the country will emerge as a challenger in the difficult space despite the high failure rates and ongoing controversies over Biogen, Inc.'s Aduhelm (aducanumab).
Smaller bioventures, rather than large pharma companies, appear to be more active at present, with several major firms including
Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
